A Review on the Advancements in COVID-19 Treatments and Vaccines Development

Duaa Aslam Chaudhry, Kainat Waqar
{"title":"A Review on the Advancements in COVID-19 Treatments and Vaccines Development","authors":"Duaa Aslam Chaudhry, Kainat Waqar","doi":"10.31703/giidr.2020(v-i).02","DOIUrl":null,"url":null,"abstract":"The outbreak of the COVID-19 pandemic that is caused by novel SARS-CoV-2 has taken the life of millions of people around the globe and has put a challenge on the whole world for identifying and developing the best possible therapies for preventing and treating this deadly infection. Clinical study and health policy and clinical interventions are required for advancements in the effective and safe treatment and prevention of COVID-19 disease. Many drugs have been tested in clinical trials for their effectiveness and safety against COVID-19. Among them, some have shown promising effects like remdesivir, the only COVID-19 drug approved by FDA till now, dexamethasone, monoclonal antibodies, etc. Biological agents have also been shown to be effective against the virus, such as tocilizumab, convalescent plasma, and interferon. The most effective medical intervention for COVID-19 is a vaccination which is currently in a development phase at a rapid pace. However, two vaccines have been authorized by the FDA and a number of vaccines are in their final clinical phase. This paper will analyze all the current advancements within the treatment against the COVID-19.","PeriodicalId":369025,"journal":{"name":"Global Immunological & Infectious Diseases Review","volume":"15 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global Immunological & Infectious Diseases Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31703/giidr.2020(v-i).02","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The outbreak of the COVID-19 pandemic that is caused by novel SARS-CoV-2 has taken the life of millions of people around the globe and has put a challenge on the whole world for identifying and developing the best possible therapies for preventing and treating this deadly infection. Clinical study and health policy and clinical interventions are required for advancements in the effective and safe treatment and prevention of COVID-19 disease. Many drugs have been tested in clinical trials for their effectiveness and safety against COVID-19. Among them, some have shown promising effects like remdesivir, the only COVID-19 drug approved by FDA till now, dexamethasone, monoclonal antibodies, etc. Biological agents have also been shown to be effective against the virus, such as tocilizumab, convalescent plasma, and interferon. The most effective medical intervention for COVID-19 is a vaccination which is currently in a development phase at a rapid pace. However, two vaccines have been authorized by the FDA and a number of vaccines are in their final clinical phase. This paper will analyze all the current advancements within the treatment against the COVID-19.
新冠肺炎治疗及疫苗研究进展综述
由新型SARS-CoV-2引起的COVID-19大流行的爆发夺走了全球数百万人的生命,并对整个世界提出了挑战,要求确定和开发预防和治疗这种致命感染的最佳疗法。在有效、安全的治疗和预防COVID-19疾病方面取得进展需要临床研究、卫生政策和临床干预措施。许多药物已经在临床试验中测试了它们对COVID-19的有效性和安全性。其中,目前FDA唯一批准的新冠药物瑞德西韦、地塞米松、单克隆抗体等已显示出良好的效果。生物制剂也被证明对病毒有效,如托珠单抗、恢复期血浆和干扰素。针对COVID-19最有效的医疗干预措施是疫苗接种,目前正处于快速发展阶段。然而,FDA已经批准了两种疫苗,许多疫苗正处于最后的临床阶段。本文将分析当前针对COVID-19治疗的所有进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信